These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 15688065)

  • 1. ADAMs: key components in EGFR signalling and development.
    Blobel CP
    Nat Rev Mol Cell Biol; 2005 Jan; 6(1):32-43. PubMed ID: 15688065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk.
    Higashiyama S; Nanba D
    Biochim Biophys Acta; 2005 Aug; 1751(1):110-7. PubMed ID: 16054021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding.
    Blobel CP
    Inflamm Res; 2002 Feb; 51(2):83-4. PubMed ID: 11926318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding.
    Schlöndorff J; Blobel CP
    J Cell Sci; 1999 Nov; 112 ( Pt 21)():3603-17. PubMed ID: 10523497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM metalloproteases and EGFR signalling.
    Gee JM; Knowlden JM
    Breast Cancer Res; 2003; 5(5):223-4. PubMed ID: 12927027
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
    Sanderson MP; Dempsey PJ; Dunbar AJ
    Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions.
    Reiss K; Saftig P
    Semin Cell Dev Biol; 2009 Apr; 20(2):126-37. PubMed ID: 19049889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors.
    Ohtsu H; Dempsey PJ; Eguchi S
    Am J Physiol Cell Physiol; 2006 Jul; 291(1):C1-10. PubMed ID: 16769815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adamalysins in biology and disease.
    van Goor H; Melenhorst WB; Turner AJ; Holgate ST
    J Pathol; 2009 Nov; 219(3):277-86. PubMed ID: 19662664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: insights on ADAM function.
    Liu H; Shim AH; He X
    J Biol Chem; 2009 Oct; 284(42):29077-86. PubMed ID: 19692335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Make) stick and cut loose--disintegrin metalloproteases in development and disease.
    Tousseyn T; Jorissen E; Reiss K; Hartmann D
    Birth Defects Res C Embryo Today; 2006 Mar; 78(1):24-46. PubMed ID: 16622847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shedding light on sheddases: role in growth and development.
    Kheradmand F; Werb Z
    Bioessays; 2002 Jan; 24(1):8-12. PubMed ID: 11782944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shedding light on ADAM metalloproteinases.
    Huovila AP; Turner AJ; Pelto-Huikko M; Kärkkäinen I; Ortiz RM
    Trends Biochem Sci; 2005 Jul; 30(7):413-22. PubMed ID: 15949939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ADAMs family of proteins: from basic studies to potential clinical applications.
    Duffy MJ; Lynn DJ; Lloyd AT; O'Shea CM
    Thromb Haemost; 2003 Apr; 89(4):622-31. PubMed ID: 12669115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.
    Kataoka H
    J Dermatol Sci; 2009 Dec; 56(3):148-53. PubMed ID: 19896805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ADAMs family of metalloproteases: multidomain proteins with multiple functions.
    Seals DF; Courtneidge SA
    Genes Dev; 2003 Jan; 17(1):7-30. PubMed ID: 12514095
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting ligand cleavage to inhibit the ErbB pathway in cancer.
    Zhou BB
    Ann N Y Acad Sci; 2005 Nov; 1059():56-60. PubMed ID: 16382043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2.
    Horiuchi K; Zhou HM; Kelly K; Manova K; Blobel CP
    Dev Biol; 2005 Jul; 283(2):459-71. PubMed ID: 15936750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAM proteases, ErbB pathways and cancer.
    Zhou BB; Fridman JS; Liu X; Friedman SM; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2005 Jun; 14(6):591-606. PubMed ID: 16004590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines.
    Singh B; Schneider M; Knyazev P; Ullrich A
    Int J Cancer; 2009 Feb; 124(3):531-9. PubMed ID: 19003995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.